AstraZeneca today announced results from a phase II study evaluating the investigational drug vandetanib for the treatment of patients with locally advanced or metastatic papillary or follicular thyroid cancer. This study, ZACTHYF, showed that treatment with vandetanib significantly improved Progression Free Survival (PFS), the primary endpoint of the study, compared to placebo (Hazard Ratio=0.63, p=0.008). Median PFS was improved by 5 months (11.0 months for vandetanib and 5.8 months for placebo patients)...
More...
More...